XML 66 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Investments (Tables)
12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Method Investments and Investments Carried Under Measurement Alternative
Equity Method Investments and Investments Carried Under the Measurement Alternative
(in thousands)
Percent Ownership1
December 31, 2024December 31, 2023
Advanced Markets Holdings25%$3,772 $4,481 
China Credit BGC Money Broking Company Limited33%23,242 21,277 
Freedom International Brokerage45%9,637 9,507 
Other2,424 2,857 
Equity method investments$39,075 $38,122 
Investments carried under measurement alternative192 192 
Total equity method and investments carried under measurement alternative$39,267 $38,314 
_______________________________________
1Represents the Company’s voting interest in the equity method investment as of December 31, 2024 and 2023.
Schedule of Financial Information for Company's Equity Method Investments
Summarized financial information for the Company’s equity method investments is as follows (in thousands):
Year Ended December 31,
202420232022
Statements of operations:
Total revenues$134,232 $111,242 $125,405 
Total expenses89,127 84,216 88,050 
   Income before income taxes$45,105 $27,026 $37,355 
December 31,
20242023
Statements of financial condition:
Cash and cash equivalents$73,519 $79,440 
Fixed assets, net2,168 1,900 
Other assets59,068 51,336 
Total assets$134,755 $132,676 
Other liabilities71,222 81,898 
Total partners’ capital63,533 50,779 
Total liabilities and partners’ capital$134,755 $132,677 
Schedule of Investments in Variable Interest Entities
The following table sets forth the Company’s investment in its unconsolidated VIE and the maximum exposure to loss (in thousands).
December 31, 2024December 31, 2023
InvestmentMaximum
Exposure to Loss
InvestmentMaximum
Exposure to Loss
Variable interest entity1
$674 $674 $2,857 $2,857 
__________________
1The Company’s maximum exposure to loss with respect to its unconsolidated VIE includes the sum of its equity investments. The Company has entered into a subordinated loan agreement with Aqua, whereby the Company agreed to lend the principal sum of $1.0 million. The Company did not recognize any interest income on the subordinated loan subsequent to being designated as a non-accrual loan in November 2022. As of December 31, 2022, the Company had written off $0.6 million of the subordinated loan, which was recorded as part of “Other expenses” on the Company’s Consolidated Statements of Operations. As of December 31, 2023, the Company had received cash payment fully satisfying the remaining subordinated loan receivable of $0.4 million.